Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03127787 · ClinicalTrials.gov registry record
Clinical Performance Evaluation of DxN CMV Assay
A clinical trial, sponsored by Beckman Coulter.
- Terminated
- Registry status
- 19
- Enrollment target
NCT03127787: Clinical Trial study, sponsored by Beckman Coulter.
NCT03127787 is a clinical trial that was terminated before completion, run by Beckman Coulter. The registered enrollment target is 19 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03127787 was terminated before completion, sponsored by Beckman Coulter.
- TERMINATED
- Registry status
- 19 participants
- Enrollment target
Study Summary
The DxN Cytomegalovirus (CMV) assay is an in vitro diagnostic assay intended as an aid in the management of CMV-infected individuals undergoing antiviral therapy. the purpose of the study is to establish the clinical performance of the DxN CMV Assay for plasma samples in the intended use population.
Primary Outcome
Resolution of CMV viremia in response to therapy as defined as 2 consecutive negative results
Interventions
- DIAGNOSTIC_TEST CMV Assay
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2016-06 |
| Est. Completion | 2017-08-30 |
Why NCT03127787 stopped before completion
NCT03127787 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 19 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which CMV Assay is the first listed.
NCT03127787 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03127787 about?
NCT03127787 is a clinical study titled "Clinical Performance Evaluation of DxN CMV Assay". The DxN Cytomegalovirus (CMV) assay is an in vitro diagnostic assay intended as an aid in the management of CMV-infected individuals undergoing antiviral therapy. the purpose of the study is to establish the clinical performance of the DxN CMV Assay for plasma samples in the intended use population.
What is the current status of trial NCT03127787?
This trial is currently terminated. The enrollment target is 19 participants. The study started on 2016-06. Estimated completion is 2017-08-30.
What interventions are being tested in trial NCT03127787?
The interventions under investigation include: CMV Assay (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03127787?
This trial is sponsored by Beckman Coulter, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia